Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders
|
|
Caribou Biosciences, Inc. (CRBU)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 |
| | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Revenues: |
| Rest of world | 0.0 | 0.1 | 0.2 | 0.3 | 0.0 | 0.1 | 0.1 | 0.5 |
| UNITED STATES | 3.7 | 3.4 | 3.5 | 3.0 | 4.2 | 2.6 | 2.4 | 3.5 |
| Total revenues | 3.8 | 3.5 | 3.7 | 3.3 | 4.2 | 2.7 | 2.6 | 4.0 |
| Revenue growth [+] | -10.4% | 31.5% | 44.3% | -16.9% | 184.0% | 68.0% | 160.1% | 232.0% |
| Rest of world | 0.0% | 125.0% | 16.3% | -28.3% | | | | |
| UNITED STATES | -10.4% | 29.6% | 45.8% | -15.4% | 183.4% | 77.1% | 129.9% | 268.0% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 3.8 | 3.5 | 3.7 | 3.3 | 4.2 | 2.7 | 2.6 | 4.0 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Selling, general and administrative [+] | 10.1 | 8.9 | 8.5 | 9.8 | 10.0 | 9.6 | 7.9 | 6.8 |
| General and administrative | 10.1 | 8.9 | 8.5 | 9.8 | 10.0 | 9.6 | 7.9 | 6.8 |
| Research and development | 26.5 | 25.7 | 25.7 | 20.0 | 22.6 | 13.9 | 15.1 | 15.8 |
| EBITDA [+] | -32.3 | -30.5 | -30.1 | | -28.1 | -20.5 | -20.1 | -18.4 |
| EBITDA growth | 14.9% | 48.6% | 49.4% | 44.6% | 75.9% | 58.6% | 30.6% | 129.4% |
| EBITDA margin | -858.9% | -871.7% | -814.5% | -803.4% | -669.7% | -771.2% | -786.7% | -461.6% |
| Depreciation and amortization | 0.6 | 0.6 | 0.5 | | 0.4 | 0.3 | 0.3 | 0.3 |
| EBIT [+] | -32.9 | -31.1 | -30.6 | -26.5 | -28.4 | -20.9 | -20.4 | -18.6 |
| EBIT growth | 15.6% | 49.2% | 49.9% | 42.5% | 78.1% | 58.3% | 30.5% | 126.2% |
| EBIT margin | -875.3% | -888.5% | -828.2% | -803.4% | -678.2% | -782.8% | -797.4% | -468.1% |
| Other income (expense), net [+] | 3.3 | 3.1 | 3.7 | -0.1 | 1.7 | 1.8 | 2.2 | -2.4 |
| Other non-operating income | 3.0 | 2.8 | 2.3 | 1.5 | 0.7 | 0.3 | 0.1 | 0.0 |
| Other | 3.0 | 2.8 | 2.3 | 1.5 | 0.7 | 0.3 | 0.1 | 0.0 |
| Pre-tax income | -29.5 | -28.0 | -26.9 | -26.6 | -26.7 | -19.1 | -18.2 | -21.0 |
| Income taxes | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.3 | 0.0 |
| Tax rate | 0.0% | 0.0% | | 0.0% | 0.0% | 0.0% | | 0.0% |
| Net income | -29.5 | -28.0 | -27.0 | -26.6 | -26.7 | -19.1 | -18.5 | -21.0 |
| Net margin | -786.1% | -800.8% | -731.0% | -806.8% | -636.9% | -716.5% | -722.1% | -527.4% |
| |
| Basic EPS [+] | ($0.48) | ($0.46) | ($0.44) | ($0.44) | ($0.44) | ($0.32) | ($0.58) | ($0.46) |
| Growth | 9.4% | 45.4% | -23.9% | -4.2% | -68.5% | -77.2% | -65.2% | -50.8% |
| Diluted EPS [+] | ($0.48) | ($0.46) | ($0.44) | ($0.44) | ($0.44) | ($0.32) | ($0.58) | ($0.46) |
| Growth | 9.4% | 45.4% | -23.9% | -4.2% | -68.5% | -77.2% | -66.1% | -50.8% |
| |
| Shares outstanding (basic) [+] | 61.4 | 61.2 | 60.8 | 60.9 | 60.8 | 60.5 | 31.7 | 45.9 |
| Growth | 1.1% | 1.1% | 92.0% | 32.7% | 492.1% | 537.4% | 260.8% | 437.5% |
| Shares outstanding (diluted) [+] | 61.4 | 61.2 | 60.8 | 60.9 | 60.8 | 60.5 | 31.7 | 45.9 |
| Growth | 1.1% | 1.1% | 92.0% | 32.7% | 492.1% | 537.4% | 270.5% | 437.5% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|